Browse evidence-based analysis of health-related claims and assertions
After drinking a sugary solution, people with early kidney disease who took pravastatin had no meaningful difference in their blood sugar two hours later compared to those who took a sugar pill.
Causal
Doctors think statins might help people who got organ transplants by calming their immune system, but there’s no solid proof yet that it actually helps them stay healthier.
Descriptive
Taking pravastatin for 3 months didn’t raise or lower average blood sugar or long-term blood sugar control in people with early kidney disease who don’t have diabetes.
Some medicines called statins might calm down certain immune cells in blood vessels in lab tests, which could help slow down artery clogging, but we don’t know for sure yet in people.
Mechanistic
Taking pravastatin for 12 weeks didn’t make the body better or worse at using insulin to control blood sugar in people with early-stage kidney disease who don’t have diabetes.
This formula was tested on data from nearly 100,000 people and might help prevent heart disease and save a lot of money — but it hasn’t been proven yet.
Scientists created a new formula that uses multiple health numbers to help figure out who’s at risk for heart disease and how to stop it — by focusing on how fast bad cholesterol moves into artery walls.
A new formula that combines cholesterol levels, blood pressure, heart rate, and heart stiffness gives risk scores for heart disease that match up with the official guidelines doctors already use.
High cholesterol, high blood pressure, fast heartbeat, and stiff heart chambers all seem to work together to push more bad cholesterol into artery walls where plaques form.
Correlational
When LDL cholesterol or Apo B particles move faster from blood into artery walls at certain spots, they build up and contribute to heart disease — this movement might be more important than just having high levels in the blood.
Having metabolic syndrome and having insulin resistance are two different things — and both of them, on their own, can tell doctors that someone is at higher risk for heart problems, even if you already know about the other.
Even if someone doesn’t have full metabolic syndrome, having high insulin resistance (a sign their body doesn’t respond well to insulin) still raises their risk of heart attacks and strokes by about 50%.
People with metabolic syndrome — a group of conditions like high blood pressure, belly fat, and high blood sugar — are nearly three times more likely to have heart problems or strokes, even if they don’t have diabetes.
Even high-dose statins don’t make you gain more weight than low-dose ones — but they still raise your diabetes risk more — meaning weight gain isn’t the reason higher doses are riskier.
People with a gene version that blocks HMGCR have slightly higher blood sugar and insulin levels — meaning their bodies are less efficient at managing sugar, even before they become diabetic.
Even though statins make you gain a little weight, that tiny gain can’t explain why you’re 11% more likely to get diabetes — something else about blocking HMGCR is making your body worse at handling sugar.
Blocking the HMGCR enzyme — whether by statin drugs or your genes — makes you about 11–12% more likely to develop type 2 diabetes, and this isn’t because the drugs lower cholesterol.
Taking statins or having a specific gene version makes people gain a little bit of weight and get a slightly bigger waist, even if they don’t eat more — this is because blocking the HMGCR enzyme affects how the body stores fat.
When immune cells can’t grab onto bad cholesterol particles using specific grabbers (Msr1 and CD36), they don’t multiply as much — showing that the cholesterol they eat makes them divide.
The cholesterol-lowering drug atorvastatin doesn’t get into the fatty plaques in arteries — so it must be working by lowering cholesterol in the blood, not by directly touching the immune cells inside the plaque.
The more fat and cholesterol packed inside a person’s artery plaque, the more the immune cells inside it are dividing — suggesting the fat itself is fueling their growth.
In mice with clogged arteries, lowering cholesterol makes the immune cells inside the plaque stop multiplying, which is why the plaque gets smaller — not because fewer cells come in or leave.
When people with clogged arteries have lower bad cholesterol in their blood, the immune cells inside the plaque stop multiplying as much, which helps shrink the plaque.
The drug lowered the activity of enzymes that break down the structural fibers in plaques, which may help keep plaques from rupturing.